Will this new program protect us from tainted drugs from overseas?
Let’s hope so.
WASHINGTON (Reuters) - U.S. regulators are asking drugmakers to submit more details about their supply chains under a pilot program announced on Wednesday to help protect patients from fake or tainted medicines from overseas.
Companies that voluntarily provide the information can get the products through U.S. border entry points more quickly, Food and Drug Administration officials said.
Concern about imported drug ingredients grew last year after the deaths of patients given tainted supplies of the blood-thinner heparin made in China. More than 80 percent of active drug ingredients are produced abroad.